Overview
Autosomal recessive spastic paraplegia type 56 (SPG56) is a rare inherited neurological condition that primarily affects the nervous system, causing progressive stiffness and weakness in the legs. It is also known as hereditary spastic paraplegia type 56 or SPG56. The disease is caused by mutations in the CYP2U1 gene, which plays a role in fatty acid metabolism in the brain and nervous system. People with SPG56 typically develop symptoms in early childhood, though the age of onset can vary. The hallmark feature is spasticity — an abnormal tightness or stiffness in the leg muscles — which leads to difficulty walking and problems with balance. Over time, the stiffness may worsen, and some individuals may also develop intellectual disability, speech difficulties, seizures, and thinning of the corpus callosum (the structure connecting the two halves of the brain). Some patients also experience dystonia, which involves involuntary muscle contractions causing abnormal postures. There is currently no cure for SPG56. Treatment focuses on managing symptoms and improving quality of life. Physical therapy, medications to reduce spasticity (such as baclofen or tizanidine), and assistive devices like braces or wheelchairs are commonly used. Occupational therapy and speech therapy may also be helpful depending on the individual's needs. Research is ongoing to better understand the disease and develop new therapies.
Also known as:
Key symptoms:
Progressive leg stiffness (spasticity)Difficulty walkingBalance problemsIntellectual disabilitySpeech difficultiesSeizuresInvoluntary muscle contractions (dystonia)Thinning of the brain's connecting structure (thin corpus callosum)Abnormal brain white matter changesExaggerated reflexesToe walkingMuscle weakness in the legsDelayed motor milestonesLearning difficulties
Clinical phenotype terms (14)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Autosomal recessive spastic paraplegia type 56.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Autosomal recessive spastic paraplegia type 56 at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Autosomal recessive spastic paraplegia type 56.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Autosomal recessive spastic paraplegia type 56.
Community
No community posts yet. Be the first to share your experience with Autosomal recessive spastic paraplegia type 56.
Start the conversation →Latest news about Autosomal recessive spastic paraplegia type 56
No recent news articles for Autosomal recessive spastic paraplegia type 56.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is the expected progression of symptoms in my child's specific case?,What therapies (physical, occupational, speech) should we start right away?,Are there any medications that can help with the leg stiffness or seizures?,Should other family members be tested for the CYP2U1 gene mutation?,Are there any clinical trials or research studies we could participate in?,What educational supports or accommodations should we request at school?,How often should we schedule follow-up appointments and brain imaging?
Common questions about Autosomal recessive spastic paraplegia type 56
What is Autosomal recessive spastic paraplegia type 56?
Autosomal recessive spastic paraplegia type 56 (SPG56) is a rare inherited neurological condition that primarily affects the nervous system, causing progressive stiffness and weakness in the legs. It is also known as hereditary spastic paraplegia type 56 or SPG56. The disease is caused by mutations in the CYP2U1 gene, which plays a role in fatty acid metabolism in the brain and nervous system. People with SPG56 typically develop symptoms in early childhood, though the age of onset can vary. The hallmark feature is spasticity — an abnormal tightness or stiffness in the leg muscles — which lead
How is Autosomal recessive spastic paraplegia type 56 inherited?
Autosomal recessive spastic paraplegia type 56 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Autosomal recessive spastic paraplegia type 56 typically begin?
Typical onset of Autosomal recessive spastic paraplegia type 56 is childhood. Age of onset can vary across affected individuals.